Emerging Non-Invasive Therapies and Their Effectiveness in the Comprehensive Management of Prostate Cancer: a Systematic Review of Current Trends and Future Directions

Tengku Rizky  Aditya; Jufriady  Ismy

doi:10.37899/journallamedihealtico.v6i3.2159

Tengku Rizky Aditya Departement of Urology, Faculty of Medicine, Syiah Kuala University / Zainoel Abidin Center General Hospital, Banda Aceh, Indonesia
Jufriady Ismy Departement of Urology, Faculty of Medicine, Syiah Kuala University / Zainoel Abidin Center General Hospital, Banda Aceh, Indonesia

DOI: https://doi.org/10.37899/journallamedihealtico.v6i3.2159

Keywords: Prostate Cancer, Non-Invasive Therapies, Androgen-Receptor Pathway, Inhibitors, Radioligand Therapy with, Lutetium, Immunotherapy

Abstract

Prostate cancer remains one of the most prevalent cancers globally, with traditional treatments like surgery, chemotherapy, and radiation often causing significant side effects and lengthy recovery. This study explores emerging non-invasive therapies—such as androgen-receptor pathway inhibitors (ARPI), radioligand therapy with lutetium, immunotherapy, high-intensity focused ultrasound (HIFU), and cryoablation—evaluating their efficacy, side effects, progression-free survival (PFS), overall survival (OS), and tumor reduction. A systematic review of recent studies revealed that ARPIs and lutetium-based radioligand therapy significantly improve PFS and OS in metastatic cases. Meanwhile, HIFU and cryoablation show promise in localized prostate cancer, offering effective tumor control with shorter recovery and fewer long-term complications than surgery. Immunotherapy, notably immune checkpoint inhibitors, demonstrated efficacy in select patient groups but posed risks of immune-related adverse events. While these therapies highlight a shift toward personalized treatment—leveraging genomic and clinical markers to optimize patient care—long-term data on their outcomes and side effects remain limited. This review underscores the potential of non-invasive therapies to transform prostate cancer management by enhancing quality of life and reducing treatment burdens. However, extensive research and clinical trials are essential to validate these approaches as standard care.

References

Abdulla, A., & Kapoor, A. (2011). Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Cuaj-Canadian Urological Association Journal, 5(2), 120–133. https://doi.org/10.5489/CUAJ.10160

Alanazi, N. S., & Alrafiah, M. H. (2024). Advances in Prostate Cancer Immunotherapy: Current Options and Emerging Novel Approaches. Annals of Urologic Oncology. https://doi.org/10.32948/auo.2024.10.20

Alowaimer, H. A., Al Shutwi, S. S., Alsaegh, M. K., Alruwaili, O. M., Alrashed, A. R., AlQahtani, S. H., ... & ALQAHTANI, S. H. (2024). Comparative efficacy of non-invasive therapies in Temporomandibular Joint Dysfunction: a systematic review. Cureus, 16(3). https://doi.org/10.7759/cureus.56713

Alshomrani, F. (2025). Non-Invasive Radiographic Techniques in Diagnosing and Treating Malignant Tumors in Animals and Humans: Current Trends and Future Directions. Pakistan Veterinary Journal, 45(1). http://dx.doi.org/10.29261/pakvetj/2025.124

Arlen, P. M. (2008). Novel approaches for the treatment of prostate cancer. Therapy, 5(1), 1–2. https://doi.org/10.2217/14750708.5.1.1

Atiq, M. O., Chandran, E. A., Karzai, F., Madan, R. A., & Aragon-Ching, J. B. (2023). Emerging treatment options for prostate cancer. Expert Review of Anticancer Therapy, 23, 625–631. https://doi.org/10.1080/14737140.2023.2208352

Beerlage, H. P. (2003). Alternative therapies for localized prostate cancer. Current Urology Reports, 4(3), 216–220. https://doi.org/10.1007/S11934-003-0072-5

Clarke, J. M., & Armstrong, A. J. (2013). Novel Therapies for the Treatment of Advanced Prostate Cancer. Current Treatment Options in Oncology, 14(1), 109–126. https://doi.org/10.1007/S11864-012-0222-4

Dawson, N. A., & Kelly, W. K. (2006). Prostate Cancer : Translational and Emerging Therapies. https://doi.org/10.3109/9781420019858

Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., ... & Manyazewal, T. (2021). New approaches and procedures for cancer treatment: Current perspectives. SAGE open medicine, 9, 20503121211034366. https://doi.org/10.1177/20503121211034366

Drouin, S. J., & Rouprêt, M. (2009). Actualités concernant la prise en charge non chirurgicale du cancer de la prostate localisé. Progres En Urologie, 19. https://doi.org/10.1016/S1166-7087(09)73900-4

Gadour, E., & Gardezi, S. A. (2025). Transjugular intrahepatic portosystemic shunt and non-selective beta-blockers act as friends or foe in decompensated cirrhosis: A comparative review. World Journal of Gastrointestinal Surgery, 17(4), 103395. https://doi.org/10.4240/wjgs.v17.i4.103395

Godbole, A. M., & Njar, V. C. O. (2011). Prostate Cancer: Current and Emerging Therapies. InTech. https://doi.org/10.5772/23893

Hedhili, L. (2024). Ippia alba essential oil: A promising complementary therapy for breast cancer. Chemistry & Biodiversity, 21(4), e202301510. https://doi.org/10.1002/cbdv.202301510

Lassi, K., & Dawson, N. A. (2009). Emerging therapies in castrate-resistant prostate cancer. Current Opinion in Oncology, 21(3), 260–265. https://doi.org/10.1097/CCO.0B013E32832A1868

Lustberg, M. B., Kuderer, N. M., Desai, A., Bergerot, C., & Lyman, G. H. (2023). Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nature Reviews Clinical Oncology, 20(8), 527-542. https://doi.org/10.1038/s41571-023-00776-9

Mazzucchelli, R., Scarpelli, M., Lopez-Beltran, A., Cheng, L., Di Primio, R., & Montironi, R. (2013). Treatment effects in prostate cancer following traditional and emerging therapies. International Journal of Immunopathology and Pharmacology, 26(2), 291–298. https://doi.org/10.1177/039463201302600202

Mir, N., Burke, O., Yates, S., Rajasekaran, T., Chan, J., Szmulewitz, R., & Kanesvaran, R. (2023). Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review. Therapeutic Advances in Medical Oncology, 15, 17588359221149887. https://doi.org/10.1177/17588359221149887

Miyamoto, C., & Achary, M. P. (2016). Emerging Modalities in Radiation Therapy for Prostate Cancer (pp. 441–448). Academic Press. https://doi.org/10.1016/B978-0-12-800077-9.00048-7

Myers, E. L., & Culton, D. A. (2025). A Narrative Review of Pemphigoid Diseases: Bridging Associations, Comorbidities, and Management. Dermatology and Therapy, 1-16. http://dx.doi.org/10.1007/s13555-025-01444-9

Pezaro, C., Marciscano, A. E., & Madan, R. A. (2018). The Winds of Change: Emerging Therapeutics in Prostate Cancer. 38(38), 382–390. https://doi.org/10.1200/EDBK_201295

Pöhlmann, J., Weller, M., Marcellusi, A., Grabe-Heyne, K., Krott-Coi, L., Rabar, S., & Pollock, R. F. (2024). High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma. Frontiers in Oncology, 14, 1368606. https://doi.org/10.3389/fonc.2024.1368606

Robb, R. A. (2002). Three-dimensional visualization and analysis in prostate cancer. Drugs of Today, 38(3), 153–165. https://doi.org/10.1358/DOT.2002.38.3.668338

Schmidt, K. T., Huitema, A. D., Chau, C. H., & Figg, W. D. (2021). Resistance to second-generation androgen receptor antagonists in prostate cancer. Nature Reviews Urology, 18(4), 209-226. https://doi.org/10.1038/s41585-021-00438-4

Singh, D., Dhiman, V. K., Pandey, M., Dhiman, V. K., Sharma, A., Pandey, H., ... & Pandey, R. (2024). Personalized medicine: An alternative for Cancer Treatment. Cancer Treatment and Research Communications, 100860. https://doi.org/10.1016/j.ctarc.2024.100860

Thoreson, G. R., Gayed, B. A., Chung, P. H., & Raj, G. V. (2014). Emerging therapies in castration resistant prostate cancer. Canadian Journal of Urology, 21, 98–105. http://www.canjurol.com/pdfs/cme/2014/15_DrThoreson.pdf

Trachtenberg, J. (2001). Emerging pharmacologic therapies for prostate cancer. Reviews in Urology, 3. https://www.ncbi.nlm.nih.gov/pubmed/16986005

Williams, S. B., Lay, A., Lau, C., Josephson, D. Y., Wilson, T. G., Choueiri, T. K., & Pal, S. K. (2011). New therapies for castrate-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 12(13), 2069–2074. https://doi.org/10.1517/14656566.2011.590133

Zafar, A., Khatoon, S., Khan, M. J., Abu, J., & Naeem, A. (2025). Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discover oncology, 16(1), 607. https://doi.org/10.1007/s12672-025-02198-8